人間で最初にアキバ
過少活動性膀胱の尿路症状が低い参加者における直接膀胱壁刺激のための埋め込み型デバイスの安全性と有効性を評価する、人間の最初の人間のオープンラベルの多施設研究
The goal of this study is to check if the study device, the Akyva System, is safe to use and to find out if it has any possible side effects. Researchers will see if the study device can help you urinate without the need for catheterization, which involves passing a catheter (small tube) into the bladder, and if there is improvement in the leftover urine amount in your bladder after urinating or trying to urinate.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Akyva Study Team
- 電話番号:+1 925-788-5929
- メール:akyvastudy@iota.bio
研究場所
-
-
Queensland
-
Woolloongabba、Queensland、オーストラリア、4102
- 募集
- Princess Alexandra Hospital
-
コンタクト:
- Wan-Yi Jiang
- 電話番号:+610731764271
- メール:wanyi.jiang@health.qld.gov.au
-
主任研究者:
- Eric Chung
-
副調査官:
- Handoo Rhee
-
-
South Australia
-
Adelaide、South Australia、オーストラリア、5006
- 募集
- Better Bladders
-
コンタクト:
- Ashani Couchman
- 電話番号:08 8164 6360
- メール:info@betterbladders.com.au
-
主任研究者:
- Ashani Couchman
-
-
Victoria
-
Melbourne N.、Victoria、オーストラリア、3051
- 募集
- Australian Prostate Centre
-
主任研究者:
- Paul Anderson, MD
-
コンタクト:
- Rachel Heerey
- 電話番号:+61 3 8373 7600
- メール:Rachel.Heerey@apcr.org.au
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
List of Eligibility Criteria apply to both Non-neurogenic and Spinal Cord Injury (SCI) Neurogenic underactive bladder study participants unless otherwise noted.
Inclusion Criteria:
- Are male or female, as assigned at birth, aged ≥ 22 years of age. (SCI Only: 22 to 70 years of age)
- Able to initiate at least three (3) volitional voiding episodes over the 7-day period based on review of their 7-day bladder diary collected between day of consent and before the implant procedure.
- Currently performing clean intermittent catheterization (CIC) for urinary retention at a rate of ≥7 catheterization episodes over the 7-day period, as reflected in a 7-day bladder diary collected between day of consent and before the implant procedure.
- Are medically fit to withstand abdominal-pelvic surgery under general anesthesia, as evaluated by standard-of-care pre-operative surgical clearance.
- Females of childbearing potential must agree to the use of contraception for the duration of the study
- Are able to understand the risks associated with the study, are willing and able to provide written informed consent prior to any study-related activity, willing and capable of participating in all follow up assessments and willing to undergo all study assessments as described at an approved clinical investigator site.
- No neurologic cause
- SCI Only: Chronic spinal cord injury (>= 6 months post-injury) with sacral/infrasacral (L1 or below) lesions, or mixed lesions associated with neurogenic lower urinary tract dysfunction (NLUTD).
Exclusion Criteria:
- Have or are scheduled for implant of any active implantable medical device (e.g., pacemaker or intrathecal or infusion pump). Individuals with implanted but inactive SNM may participate. Individuals with implanted and inactive SNM devices may participate.
- Have metallic implants/fragments within 2 cm of the Lead paddles.
- Have a documented allergy to tissue contacting Akyva System materials: tecothane, titanium, silicone, epoxy, stainless steel, nickel/cobalt/chromium/molybdenum, polyether ether ketone (PEEK), platinum, iridium, polymethylpentene (TPX), polycarbonate, polyester.
- In the opinion of the Investigator(s), participants who need or are likely to need magnetic resonance imaging (MRI) as part of their routine care for the duration of the study. If MRI is clinically indicated, during or after the study, explant of the Akyva System may be required
- Have active infection requiring treatment with antibiotics at Screening, unless cleared before Akyva System Surgical Implant (Visit 2).
- Previous or planned major surgical procedures, including, but not exclusive to: prior mesh implant < 3 years old, OR history of mesh-related complications (e.g. erosion, exposure, infection, chronic pain), augmentation cystoplasty, urinary diversion, bladder reconstruction, and any other procedure that increases the risk of device implantation.
- Active medical conditions that could increase the risk of surgery or device implantation, including, but not exclusive to: ascites, severe inflammatory diseases, bleeding or clotting disorders, severe cardiopulmonary disease, etc.
- Have a significant clinical finding that would, in the opinion of the Surgical Co-Investigator, increase the risk associated with the implant procedure (e.g. ascites, severe inflammatory disease, bleeding or clotting disorder, other interfering devices etc.).
- Have complete urinary retention.
- An acontractile detrusor.
- Any evidence of current bladder outlet obstruction from any cause, including, but not exclusive to, bladder neck stenosis, prostatic hypertrophy, or urethral stricture. Participants with prior surgical treatment of BPH with no clinical evidence of obstruction and do not require routine MRI may be included.
- Type I or Type II diabetes, with an HbA1C ≥ 7.0% within the last 60 days from consent.
- Have documented renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) ≤ 50 mL/min/1.73 m² or
- Evidence of moderate to severe hydronephrosis (grade 3 or 4 per Society for Fetal Urology [SFU] grading scale) on renal and bladder ultrasound within 60 days prior to implant.
- Have any history of dialysis or kidney transplant.
- Have more than 1 active/symptomatic bladder stone and/or have a bladder stone > 5 mm in size.
- Have a symptomatic kidney stone requiring intervention within the last 12 months, and/or have a kidney stone > 5 mm in size.
- Have any history of bladder cancer.
- Locally advanced or metastatic thoracic, abdominal, or pelvic malignancy other than bladder cancer unless disease-free for five (5) years or greater.
- Have any history of radiation cystitis.
- Have had botulinum toxin injection in the bladder or pelvic floor in the past 6 months measured from the day of consent.
- Diagnosis of overactive bladder (OAB), with urge urinary incontinence (OAB-wet), whether treated or untreated.
- In the opinion of the PI, an iatrogenic cause, e.g., prior pelvic surgery, multiple or complicated deliveries, and/or other potential events are the suspected cause of UAB symptoms.
- Currently using an indwelling (e.g. Foley) catheter for bladder emptying, with an exception for nighttime-only use.
- Currently using suprapubic catheters, unless the suprapubic catheter is removed at least 30 days prior to implant.
- Participants who are unable to discontinue anticoagulant therapy for the implant procedure.
- Females of childbearing potential who are pregnant, not using medical birth control or who are planning to become pregnant during the anticipated study period.
- Predicted life expectancy of less than two years from the day of consent.
- Any condition that, in the Investigator's opinion, would preclude participation in the study (e.g., have a medical condition that may interfere with interpretation of study results, inability to adhere to the visit schedule, poor cognitive abilities, poor compliance with treatment regimen, or poor dexterity to use the system etc.).
- Previously (within 5.5x the terminal half-life (drug trial) or 8 weeks (device trial) of the screening visit) or currently enrolled in another investigational drug or device trial that targets lower urinary tract symptoms/function.
- Vulnerable persons such as prisoners, mentally-disabled or cognitively impaired, homeless or economically disadvantaged, nursing home patients, or others requiring legally authorized representatives.
- Participants that work in an environment with exposures to high levels of electromagnetic interference such as working with high powered electrical equipment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Akyva System
Participants in the study arm will receive a device called the "Akyva System." The Akyva System is an implantable device intended to electrically stimulate the bladder muscle that controls bladder emptying or urination. Both non-neurogenic and spinal cord injury neurogenic underactive bladder patients will be included. |
The Akyva System is an implantable device intended to electrically stimulate the bladder muscle that controls bladder emptying or urination |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To characterize the safety of implantation and use of the Akyva System
時間枠:From enrollment to 6 and 18 months
|
Justification of Endpoint: As this is a first-in-human study, the primary objective is to assess the safety of the implantation and use of the Akyva System for bladder wall stimulation. Treatment-emergent incidence rates of ADEs, SADEs, and UADEs |
From enrollment to 6 and 18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To assess the effect of bladder wall stimulation on bladder emptying
時間枠:From enrollment through 18 months
|
Justification of Endpoint: This would be assessed by decrease in residual urine/increase in voiding efficiency or decreases in catheter reliance.
|
From enrollment through 18 months
|
|
To assess the surgical feasibility of the Akyva system implantation procedure based on clinical usability survey data
時間枠:Perioperative/Periprocedural
|
Justification of Endpoint: Although the surgical approach to accessing the anterior-lateral bladder wall is common in practice, the placement and use of the Akyva IPG and Leads is unique. This endpoint aims to analyze the feasibility of the Akyva implantation.
|
Perioperative/Periprocedural
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Mike Woods, MD、iota Biosciences
- スタディディレクター:Carmela Cusumano, MS, CCRP, CMDA、Iota Biosciences
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- iota-AS-AUS-001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。